Fellowship · New York, NY
Sponsored by New York Presbyterian Hospital · Director Dora Leung
Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS.
The New England journal of medicine · 2022 · 755 citations · Jinsy Andrews
Safety and efficacy of rozanolixizumab in patients with generalised myasthenia gravis (MycarinG): a randomised, double-blind, placebo-controlled, adaptive phase 3 study.
The Lancet. Neurology · 2023 · 231 citations · Ali Habib
OxPhos defects cause hypermetabolism and reduce lifespan in cells and in patients with mitochondrial diseases.
Communications biology · 2023 · 130 citations · Michio Hirano
Design of a Randomized, Placebo-Controlled, Phase 3 Trial of Tofersen Initiated in Clinically Presymptomatic SOD1 Variant Carriers: the ATLAS Study.
Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2022 · 153 citations · Jinsy Andrews
Long-Term Tofersen in SOD1 Amyotrophic Lateral Sclerosis.
JAMA neurology · 2026 · 17 citations · Jinsy Andrews
Circulating markers of NADH-reductive stress correlate with mitochondrial disease severity.
The Journal of clinical investigation · 2021 · 177 citations · Michio Hirano
Small fiber neuropathy associated with SARS-CoV-2 infection.
Muscle & nerve · 2022 · 112 citations · Lan Zhou
Neuromonitoring detects brain injury in patients receiving extracorporeal membrane oxygenation support.
The Journal of thoracic and cardiovascular surgery · 2023 · 57 citations · Eva Ritzl